Biomoda, Inc., maker of patented early lung cancer detection testing and other cancer diagnostic technology, confirmed today that it is continuing to expand its patent portfolio with a unique patent pending for the use of its patented porphyrin molecule to detect different cell variations of lung cancer. “It is important that the Company protect all the various uses of this molecule, setting up a barrier to entry for competition,” said John Cousins, President of Biomoda. “We are protecting the value of our core patents with patents that detail improvements and new uses of our strong, innovative technology. This prevents those on the periphery from attempting to target our patents with a so-called ‘picket fence’ of minor patents that could weaken our powerful market position.”